Nixon Peabody Trust Co. Has $16.72 Million Stake in Johnson & Johnson (NYSE:JNJ)

Nixon Peabody Trust Co. increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 646.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 106,694 shares of the company’s stock after purchasing an additional 92,406 shares during the quarter. Johnson & Johnson makes up approximately 1.9% of Nixon Peabody Trust Co.’s portfolio, making the stock its 13th largest position. Nixon Peabody Trust Co.’s holdings in Johnson & Johnson were worth $16,723,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in JNJ. Skopos Labs Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $2,283,000. Objectivity Squared LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter worth $405,000. Congress Wealth Management LLC DE raised its holdings in shares of Johnson & Johnson by 7.0% during the fourth quarter. Congress Wealth Management LLC DE now owns 87,526 shares of the company’s stock worth $13,719,000 after acquiring an additional 5,723 shares in the last quarter. Hoylecohen LLC boosted its position in Johnson & Johnson by 0.8% during the fourth quarter. Hoylecohen LLC now owns 129,764 shares of the company’s stock valued at $20,339,000 after purchasing an additional 1,063 shares during the last quarter. Finally, HCR Wealth Advisors grew its stake in Johnson & Johnson by 28.6% in the fourth quarter. HCR Wealth Advisors now owns 11,679 shares of the company’s stock valued at $1,831,000 after purchasing an additional 2,594 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ stock traded down $2.73 during mid-day trading on Friday, reaching $146.97. 9,520,576 shares of the stock traded hands, compared to its average volume of 7,234,254. The firm has a market capitalization of $353.71 billion, a PE ratio of 9.16, a P/E/G ratio of 2.49 and a beta of 0.55. The business has a 50-day moving average of $151.31 and a two-hundred day moving average of $155.07. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.68 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.64 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a yield of 3.37%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is 30.92%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on JNJ. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price target for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Bank of America reduced their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday, May 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research report on Wednesday. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.86.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.